BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36854508)

  • 1. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
    Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
    Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.
    Ueshima K; Nishida N; Hagiwara S; Aoki T; Minami T; Chishina H; Takita M; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Hiraoka A; Johnson P; Kudo M
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31284682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
    Tada T; Kumada T; Hiraoka A; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
    Sci Rep; 2021 Jul; 11(1):14474. PubMed ID: 34262065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
    Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
    Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
    Xu MH; Huang C; Li ML; Zhu XD; Tan CJ; Zhou J; Fan J; Sun HC; Shen YH
    Cancer Med; 2023 Apr; 12(8):9202-9212. PubMed ID: 36790032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
    Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
    Bang K; Casadei-Gardini A; Yoo C; Iavarone M; Ryu MH; Park SR; Kim HD; Yoon YI; Jung DH; Park GC; Ahn CS; Moon DB; Hwang S; Kim KH; Song GW; Mazzarelli C; Alimenti E; Chan SL; De Giorgio M; Ryoo BY; Lee SG
    Cancer Med; 2023 Feb; 12(3):2572-2579. PubMed ID: 36812124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Uchikawa S; Kawaoka T; Ando Y; Yamaoka K; Kosaka Y; Suehiro Y; Fujii Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Chayama K; Aikata H
    Oncology; 2020; 98(10):727-733. PubMed ID: 32712613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
    Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
    Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
    Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
    Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib.
    Rimini M; Kudo M; Tada T; Shigeo S; Kang W; Suda G; Jefremow A; Burgio V; Iavarone M; Tortora R; Marra F; Lonardi S; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Kumada T; Iwamoto H; Aoki T; Goh MJ; Sakamoto N; Siebler J; Hiraoka A; Niizeki T; Ueshima K; Sho T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Tani J; Nakamura S; Nouso K; Tsutsui A; Nagano T; Takaaki T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y; Cucchetti A; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Dec; 6(6):100330. PubMed ID: 34847382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Tanaka H; Tamai T; Koizumi Y; Hiasa Y; Michitaka K; Kudo M; ;
    Oncology; 2019; 97(5):277-285. PubMed ID: 31307035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).
    Kariyama K; Hiraoka A; Kumada T; Yasuda S; Toyoda H; Tsuji K; Hatanaka T; Kakizaki S; Naganuma A; Tada T; Takaguchi K; Itobayashi E; Ishikawa T; Shimada N; Tsutsui A; Nagano T; Imai M; Nakamura S; Wakuta A; Miyake N; Shiota S; Nouso K
    J Gastroenterol; 2022 Aug; 57(8):581-586. PubMed ID: 35763116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
    Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
    Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review.
    Bannaga A; Arasaradnam RP
    World J Gastroenterol; 2020 Sep; 26(33):5022-5049. PubMed ID: 32952347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection.
    Amisaki M; Uchinaka E; Morimoto M; Tokuyasu N; Sakamoto T; Honjo S; Saito H; Fujiwara Y
    Hepatobiliary Pancreat Dis Int; 2018 Dec; 17(6):502-509. PubMed ID: 30077606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.